Clinical Parkinsonism Related Disorders最新文献

{"title":"The impact of an active lifestyle on markers of intestinal inflammation in Parkinson’s disease: Preliminary findings","authors":"Nesrine Chtioui ,&nbsp;Christian Duval ,&nbsp;David H. St-Pierre","doi":"10.1016/j.prdoa.2025.100301","DOIUrl":"10.1016/j.prdoa.2025.100301","url":null,"abstract":"<div><div>Alterations in the gut microbiota leading to intestinal inflammation and decreased levels of Short Chain Fatty Acids (SCFA) has been observed in Parkinson’s disease (PD).</div></div><div><h3>Objective</h3><div>The aim of this study was to compare these factors between physically active and less active people with PD.</div></div><div><h3>Methods</h3><div>Stool, plasma samples and clinical data were collected from 35 people with PD (20 men and 15 women, mean age 66 years). Their level of physical activity was retrospectively assessed using the International Physical Activity Questionnaire (IPAQ). Participants were divided into two groups based on their physical activity level: Active and Inactive. Both SCFA and calprotectin, a marker of intestinal inflammation, were respectively measured by GC–MS and ELISA, according to standardized, validated protocols.</div></div><div><h3>Results</h3><div>Age, disease stage (Hoen &amp; Yahr) and Montreal Cognitive Assessments (MoCA) were similar between groups. Acetate, propionate, and butyrate levels were significantly higher in the Active group than in the Inactive group. In addition, fecal calprotectin was significantly lower in the Active group than in the Inactive group. The constipation values were significantly lower in the Active group.</div></div><div><h3>Conclusion</h3><div>Our results suggest that an active lifestyle with regular physical activity is beneficial in patients with PD, through increased production of SCFA by the gut microbiome, and reduced intestinal inflammation and constipation.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100301"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating YouTube as a source of information on hemifacial spasm","authors":"Kimberly L. Po ,&nbsp;Alfeo Julius R. Sy ,&nbsp;Roland Dominic G. Jamora","doi":"10.1016/j.prdoa.2025.100311","DOIUrl":"10.1016/j.prdoa.2025.100311","url":null,"abstract":"<div><h3>Background and Objectives</h3><div>Patients increasingly turn to YouTube for trustworthy health-related information, prompting a study to evaluate the quality and reliability of videos about hemifacial spasms (HFS) available on the platform.</div></div><div><h3>Materials and Methods</h3><div>In August 2024, a systematic search was conducted using a formal strategy to identify relevant videos. Two independent neurology resident physicians reviewed each video, scoring it with the validated modified DISCERN (mDISCERN) tool for reliability and the Global Quality Scale (GQS) for content quality. Videos were categorized based on their purpose and assessed for video/audio quality, accuracy, comprehensiveness, and procedure-specific content.</div></div><div><h3>Results</h3><div>The study included 44 videos. According to GQS, 17 (38.6 %) were rated as high quality, 14 (31.8 %) as good, 5 (17 %) as medium, and 8 (18.2 %) as poor quality. On the mDISCERN scale, 24 (54.5 %) were deemed reliable, while 9 (20.5 %) were unreliable. Videos created by physicians, academic institutions, and reputable health information websites scored higher on both mDISCERN and GQS compared to other sources. A strong positive correlation was found between mDISCERN and GQS scores (r = 0.925, p &lt; 0.001), indicating that higher reliability was linked to better content quality.</div></div><div><h3>Conclusion</h3><div>YouTube offers valuable resources for HFS patients and caregivers. Videos produced by healthcare professionals and academic institutions offered particularly accurate insights, enhancing patients’ understanding of the condition’s pathophysiology and treatment options, and serving as a useful complement to healthcare professionals’ knowledge. Healthcare professionals and academic institutions have a pivotal role in creating and promoting high-quality educational content. Future efforts should focus on increasing the availability of reliable, expert-verified videos to improve overall quality of information accessible to patients.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100311"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autonomic dysfunction in progressive supranuclear Palsy: A retrospective study","authors":"Yichun Wang ,&nbsp;Manqing Xie ,&nbsp;Dan Xu ,&nbsp;Yanhong Wang ,&nbsp;Han Wang","doi":"10.1016/j.prdoa.2025.100310","DOIUrl":"10.1016/j.prdoa.2025.100310","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to investigate the characteristics of autonomic dysfunction in progressive supranuclear palsy (PSP) compared to Parkinson’s disease (PD) and multiple system atrophy-parkinsonian type (MSA-P).</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 128 patients who underwent multidisciplinary team (MDT) intervention at Peking Union Medical College Hospital between March 31, 2021, and November 22, 2023. A total of 16 PSP, 27 MSA-P, and 11 PD patients were included. Autonomic dysfunction was assessed using the SCOPA-AUT scale and medical record data, analyzed with IBM SPSS Statistics 26.</div></div><div><h3>Results</h3><div>SCOPA-AUT revealed varying degrees of autonomic dysfunction across all groups. The total SCOPA-AUT score was lower in PSP (16.88 ± 6.70) than in MSA-P (23.33 ± 8.80) (p = 0.019), but not significantly different from PD (18.64 ± 9.80). All five SCOPA-AUT subscales were affected in PSP, though significant differences were found only in urinary control (p = 0.006) and urinary storage (p = 0.008) scores between PSP and MSA-P. Orthostatic hypotension was clinically identified in 7.7 % of PSP, 66.7 % of MSA-P, and 27.3 % of PD patients, with a significant difference between PSP and MSA-P (p &lt; 0.001). Residual urine volume in MSA-P (137.5 [75.5–190.25] mL) was significantly higher than in PD (34.5 [1.50–60.00] mL, p &lt; 0.001) and PSP (9.95 [1.13–56.25] mL, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Our findings indicate that PSP presents with various forms of autonomic dysfunction, as assessed by SCOPA-AUT, with similarities to both MSA-P and PD. Objective measures, such as orthostatic blood pressure assessments and residual urine ultrasound, can provide additional insights into autonomic dysfunction in PSP.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100310"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the enigmatic: Primary progressive apraxia of speech – A case report","authors":"Mateusz Bernad ,&nbsp;Renata Kowalska-Taczanowska ,&nbsp;Karolina Duszyńska- Wąs ,&nbsp;Joanna Mączewska ,&nbsp;Piotr Alster ,&nbsp;Dariusz Koziorowski ,&nbsp;Monika Figura","doi":"10.1016/j.prdoa.2025.100304","DOIUrl":"10.1016/j.prdoa.2025.100304","url":null,"abstract":"<div><div>Primary progressive apraxia of speech (PPAOS) is a rare neurodegenerative disorder that saliently affects motor speech programming and planning. Linguistic function remains intact in the early stages of PPAOS.</div><div>Although PPAOS shares a similar symptomatology to conditions such as primary progressive aphasia (PPA) and dysarthria, it is important to remember that this disorder constitutes its own distinct clinical syndrome. PPAOS is characterized by an individually variable disease course, with a steady progression in speech deterioration. In later stages, this disorder may additionally present with symptoms such as oral apraxia, dysarthria, dysphagia, aphasia, and parkinsonian syndromes similar to either progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS). 4-repeat tauopathy is the most common pathology associated with PPAOS. In this study, we present a case of a female patient suffering from PPAOS, detailing her clinical course during a 44-year long follow-up. As PPAOS is a disorder with a worldwide poorly-documented prevalence, there is limited data in literature on the subject. We thus bring this case to public discussion. We also recommend further investigating this disorder, as we would then be able to unify diagnostic and therapeutic approaches for PPAOS.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100304"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPG7 mutation – Novel phenotypic presentation mimicking idiopathic Parkinson’s disease","authors":"Karri Madhavi,&nbsp;Rukmini Mridula Kandadai,&nbsp;Sruthi Kola,&nbsp;Rupam Borgohain,&nbsp;Rajesh Alugolu,&nbsp;VVSRK Prasad","doi":"10.1016/j.prdoa.2024.100280","DOIUrl":"10.1016/j.prdoa.2024.100280","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100280"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142651162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?","authors":"Hiu Fung Wu ,&nbsp;Ellen Lok Man Yu ,&nbsp;Bun Sheng ,&nbsp;Kwok Kui Wong ,&nbsp;Man Au Yeung ,&nbsp;Wa Tai Wong ,&nbsp;Hon Hang Kwan ,&nbsp;Lun Pei Ng ,&nbsp;Chun Hin Cheung ,&nbsp;Yan Lok Lam ,&nbsp;Yat Kwan Chan","doi":"10.1016/j.prdoa.2024.100235","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100235","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the incidence of Impulse control and related behavioral disorders (ICRD) in Chinese Idiopathic Parkinson Disease (IPD) patients treated with different dopamine agonists (DA), and their clinical characteristics and associated risk factors.</p></div><div><h3>Methods</h3><p>This was an observational cohort study based on clinical interviews and medical records of IPD patients treated with DA for &gt;6 months in three hospitals in Hong Kong. The short version of Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP-S) was used to screen for ICRD. ICRD incidence among different DA, clinical characteristics and risk factors were examined.</p></div><div><h3>Results</h3><p>Incidence of ICRD was analyzed in 311 patients taking their first, single DA. 43 patients (13.8 %) developed ICRD. The mean duration of IPD was 8.5 ± 5.6 years and median HY stage was 2.5. Bromocriptine and rotigotine users had lower ICRD incidence rate. Both pramipexole [adjusted HR 7.28 (2.46–21.54), p &lt; 0.001] and ropinirole [adjusted HR 6.53 (2.67–15.99), p &lt; 0.001] were independently associated with higher risk of ICRD compared to bromocriptine in multivariate analysis. Similarly, pramipexole and ropinirole appeared to carry higher risk compared to rotigotine but did not reach statistical significance. Male [adjusted HR 2.24 (1.07–4.72), p = 0.033], younger IPD onset [adjusted HR 2.99 (1.44–6.19) for onset &lt; 50 year, p = 0.003] and history of psychiatric disorders [adjusted HR 2.80 (1.39–5.62), p = 0.004] were other independent risk factors.</p></div><div><h3>Conclusion</h3><p>Bromocriptine and probably rotigotine carried a lower ICRD risk compared to pramipexole and ropinirole.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100235"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000045/pdfft?md5=9fc58f77d2de8691adeff611604c5e99&pid=1-s2.0-S2590112524000045-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139406308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm","authors":"Deepmala Nandanwar,&nbsp;Daniel D. Truong","doi":"10.1016/j.prdoa.2024.100271","DOIUrl":"10.1016/j.prdoa.2024.100271","url":null,"abstract":"<div><div>Multiple system atrophy (MSA) is a heterogenous condition, presenting with core clinical features of autonomic dysfunction, parkinsonism, and/or cerebellar ataxia. The presence of alpha-synuclein glial cytoplasmic inclusion is the hallmark of MSA. It shares a common pathological origin with Parkinson’s disease (PD) and Lewy body dementia (DLB) and they are collectively grouped as “synucleinopathies.” The pathological synuclein protein is now well- recognized in skin biopsies of these patients. Besides the pathological findings, radiological investigation is a useful diagnostic tool. Brain MRI helps rule out other etiologies, and findings like the “Hot-cross bun” sign, “putaminal atrophy,” and “infratentorial findings” can assist with the diagnosis of MSA. Cardiac MIBG scan, autonomic testing, urodynamic studies can help differentiate MSA from other conditions. Although diagnostic tools are available for MSA diagnosis, clarity is needed on when to use these tests. We suggest a diagnostic algorithm to navigate the use of these tests. However, this algorithm is not intended to replace the use of current MDS diagnostic criteria of MSA.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100271"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical prediction of GBA carrier status in Parkinson’s disease","authors":"Julia Greenberg ,&nbsp;Kelly Astudillo ,&nbsp;Steven J. Frucht ,&nbsp;Adeen Flinker ,&nbsp;Giulietta M. Riboldi","doi":"10.1016/j.prdoa.2024.100251","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100251","url":null,"abstract":"<div><h3>Introduction</h3><p>Given the unique natural history of <em>GBA</em>-related Parkinson’s disease (<em>GBA</em>-PD) and the potential for novel treatments in this population, genetic testing prioritization for the identification of <em>GBA</em>-PD patients is crucial for prognostication, individualizing treatment, and stratification for clinical trials. Assessing the predictive value of certain clinical traits for the <em>GBA</em>-variant carrier status will help target genetic testing in clinical settings where cost and access limit its availability.</p></div><div><h3>Methods</h3><p>In-depth clinical characterization through standardized rating scales for motor and non-motor symptoms and self-reported binomial information of a cohort of subjects with PD (n = 100) from our center and from the larger cohort of the Parkinson’s Progression Marker Initiative (PPMI) was utilized to evaluate the predictive values of clinical traits for <em>GBA</em> variant carrier status. The model was cross-validated across the two cohorts.</p></div><div><h3>Results</h3><p>Leveraging non-motor symptoms of PD, we established successful discrimination of <em>GBA</em> variants in the PPMI cohort and study cohort (AUC 0.897 and 0.738, respectively). The PPMI cohort model successfully generalized to the study cohort data using both MDS-UPDRS scores and binomial data (AUC 0.740 and 0.734, respectively) while the study cohort model did not.</p></div><div><h3>Conclusions</h3><p>We assessed the predictive value of non-motor symptoms of PD for identifying <em>GBA</em> carrier status in the general PD population. These data can be used to determine a simple, clinically oriented model using either the MDS-UPDRS or subjective symptom reporting from patients. Our results can inform patient counseling about the expected carrier risk and test prioritization for the expected identification of <em>GBA</em> variants.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100251"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000227/pdfft?md5=b31ac295a3ba583c0d89bd9fdec5c51e&pid=1-s2.0-S2590112524000227-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223]","authors":"Bruno Bergmans ,&nbsp;Veronica Clark ,&nbsp;Stuart H. Isaacson ,&nbsp;Tobias Bäumer","doi":"10.1016/j.prdoa.2024.100250","DOIUrl":"10.1016/j.prdoa.2024.100250","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100250"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000215/pdfft?md5=048097608faca594fde04c083b24c4b3&pid=1-s2.0-S2590112524000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis","authors":"Stuart H. Isaacson ,&nbsp;Rajesh Pahwa ,&nbsp;Fernando Pagan ,&nbsp;Victor Abler ,&nbsp;Daniel Truong","doi":"10.1016/j.prdoa.2024.100256","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100256","url":null,"abstract":"<div><h3>Introduction</h3><p>Parkinson’s disease (PD) is associated with increased mortality risk (MR), reflecting progression of motor and nonmotor symptoms. PD psychosis (PDP), a common nonmotor symptom, increases with prolonged disease and elevates the MR of PD even further. Pimavanserin is the only FDA–approved treatment for PDP. This review summarizes real-world evidence around the MR of patients with PDP treated with pimavanserin versus off-label atypical antipsychotics.</p></div><div><h3>Methods</h3><p>A PubMed search was conducted using the following search terms: <em>pimavanserin</em> AND <em>antipsychotic</em> AND <em>mortality</em> AND <em>Parkinson’s disease</em> AND <em>psychosis</em>. Inclusion criteria specified the entry of retrospective, observational, and open-label studies comparing pimavanserin to atypical antipsychotics or untreated controls.</p></div><div><h3>Results</h3><p>A total of 10 of the 32 articles met inclusion criteria. Among five comparisons of pimavanserin with atypical antipsychotics, two were large (n = 21,719; n = 21,975), representative, Medicare-database studies, which demonstrated comparable or lower all-cause pimavanserin MR. Among three pimavanserin versus control studies, two reported lower or comparable pimavanserin MR and one, long-term care study reported higher MR for pimavanserin versus non-pimavanserin treated patients with unknown PDP status. Two open-label extensions reported pimavanserin mortality rates of 6.45 and 18.8 deaths per 100 patient-years, which are comparable to, or lower than, mortality rates for PD, PDP, and other atypical antipsychotics. Most studies (70 %; 7 of 10) demonstrated pimavanserin’s MR was lower than or similar to other atypical antipsychotics or untreated controls.</p></div><div><h3>Conclusions</h3><p>Pimavanserin did not increase the MR in PDP. Pimavanserin’s MR appears to be comparable to or lower than other atypical antipsychotics prescribed for PDP, including quetiapine.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100256"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000276/pdfft?md5=80617a944c3e1b63d785e65ea66903a6&pid=1-s2.0-S2590112524000276-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}